KR20240131349A - 통증의 치료를 위한 조성물 및 방법 - Google Patents
통증의 치료를 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20240131349A KR20240131349A KR1020247021912A KR20247021912A KR20240131349A KR 20240131349 A KR20240131349 A KR 20240131349A KR 1020247021912 A KR1020247021912 A KR 1020247021912A KR 20247021912 A KR20247021912 A KR 20247021912A KR 20240131349 A KR20240131349 A KR 20240131349A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleotides
- sirna molecule
- chemical formula
- formula
- antisense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284957P | 2021-12-01 | 2021-12-01 | |
| US63/284,957 | 2021-12-01 | ||
| PCT/US2022/080764 WO2023102488A2 (en) | 2021-12-01 | 2022-12-01 | Compositions and methods for treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240131349A true KR20240131349A (ko) | 2024-08-30 |
Family
ID=86613161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247021912A Pending KR20240131349A (ko) | 2021-12-01 | 2022-12-01 | 통증의 치료를 위한 조성물 및 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250109402A1 (https=) |
| EP (1) | EP4441228A2 (https=) |
| JP (1) | JP2024542738A (https=) |
| KR (1) | KR20240131349A (https=) |
| CN (1) | CN118632929A (https=) |
| AU (1) | AU2022403005A1 (https=) |
| CA (1) | CA3240948A1 (https=) |
| MX (1) | MX2024006649A (https=) |
| WO (1) | WO2023102488A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025108284A1 (en) * | 2023-11-20 | 2025-05-30 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of sodium voltage-gated channel alpha subunit 9 (scn9a) |
| WO2025140551A1 (en) * | 2023-12-29 | 2025-07-03 | Neuro3 Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING NaV1.7 (SCN9A) -ASSOCIATED DISORDERS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009033027A2 (en) * | 2007-09-05 | 2009-03-12 | Medtronic, Inc. | Suppression of scn9a gene expression and/or function for the treatment of pain |
-
2022
- 2022-12-01 KR KR1020247021912A patent/KR20240131349A/ko active Pending
- 2022-12-01 CA CA3240948A patent/CA3240948A1/en active Pending
- 2022-12-01 EP EP22902400.5A patent/EP4441228A2/en active Pending
- 2022-12-01 AU AU2022403005A patent/AU2022403005A1/en active Pending
- 2022-12-01 CN CN202280087774.5A patent/CN118632929A/zh active Pending
- 2022-12-01 US US18/714,751 patent/US20250109402A1/en active Pending
- 2022-12-01 JP JP2024532733A patent/JP2024542738A/ja active Pending
- 2022-12-01 MX MX2024006649A patent/MX2024006649A/es unknown
- 2022-12-01 WO PCT/US2022/080764 patent/WO2023102488A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023102488A8 (en) | 2023-08-10 |
| EP4441228A2 (en) | 2024-10-09 |
| JP2024542738A (ja) | 2024-11-15 |
| MX2024006649A (es) | 2024-08-15 |
| US20250109402A1 (en) | 2025-04-03 |
| WO2023102488A3 (en) | 2023-09-14 |
| CN118632929A (zh) | 2024-09-10 |
| WO2023102488A2 (en) | 2023-06-08 |
| AU2022403005A1 (en) | 2024-07-11 |
| CA3240948A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4594501A2 (en) | Sirna compositions and methods targeting microtubule associated protein tau nucleic acids | |
| KR20240131349A (ko) | 통증의 치료를 위한 조성물 및 방법 | |
| EP4594495A2 (en) | Compositions and methods for treatment of neuroinflammatory diseases | |
| EP4594499A2 (en) | Compositions and methods for treatment of neurodegenerative diseases | |
| WO2024073592A2 (en) | Compositions and methods for treatment of neurological disorders | |
| WO2023060092A1 (en) | Compositions and methods for treatment of prion diseases | |
| KR20240159663A (ko) | 뇌전증의 치료를 위한 조성물 및 방법 | |
| WO2024073596A2 (en) | Compositions and methods for treatment of spinocerebellar ataxias | |
| EP4594503A2 (en) | Compositions and methods for treatment of neuroinflammatory diseases | |
| KR20250075687A (ko) | 헌팅턴병 치료용 조성물 및 방법 | |
| WO2023225495A2 (en) | Compositions and methods for treatment of microsatellite dna expansion disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |